DRX 254
Alternative Names: Deuterated CC 122; Deuterium stabilised CC 122; DRX-254Latest Information Update: 03 Dec 2019
Price :
$50 *
At a glance
- Originator DeuteRx
- Class Antineoplastics; Piperidones; Quinazolines
- Mechanism of Action Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Haematological-malignancies in USA (PO)
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours in USA (PO)